Long-term follow-up of CALGB 40502/NCCTG N063H (Alliance): A randomized phase III trial of weekly paclitaxel (P) compared to weekly nanoparticle albumin bound nab-Paclitaxel (NP) or ixabepilone (Ix) plus /- bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer (MBC)

被引：0

作者：

Rugo, Hope S.

Barry, William T.

Moreno-Aspitia, Alvaro

Lyss, Alan

Huebner, Luke

Mayer, Erica L.

Naughton, Michael

Layman, Rachel M.

Carey, Lisa A.

Somer, Robert A.

Toppmeyer, Debra

Velasco, Mario

Perez, Edith A.

Hudis, Cliff A.

Winer, Eric

机构：

[1] Univ Calif San Francisco, Comprehens Canc Ctr, San Francisco, CA 94143 USA

[2] Dana Farber Partners CancerCare, Alliance Stat & Data Ctr, Boston, MA USA

[3] Mayo Clin, Jacksonville, FL 32224 USA

[4] Heartland Canc Res NCORP, St Louis, MO USA

[5] Mayo Clin, Alliance Stat & Data Ctr, Rochester, NY USA

[6] Dana Farber Partners CancerCare, Boston, MA USA

[7] Washington Univ, Sch Med, St Louis, MO 63130 USA

[8] MD Anderson Comprehens Canc Ctr, Houston, TX USA

[9] Univ N Carolina, Chapel Hill, NC USA

[10] Cooper Univ Hosp, Camden, NJ USA

[11] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[12] Genentech Inc, San Francisco, CA 94080 USA

[13] Mem Sloan Kettering Canc, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

GS3-06

引用

页数：1